OR WAIT null SECS
A group of investors including The Halifax Group and SV Life Sciences announced a series of acquisitions that are an integral part of its strategy to build a global differentiated biopharmaceutical services company.
Led by Patrick K. Donnelly, one of the investors and former CEO of PRA International, the investment group purchased all shares of ClinResearch and ADDPLAN, global leaders in adaptive trial services and software, and Fulcrum Pharma, a UK-based company that provides comprehensive drug development, regulatory and safety services.
“With these announcements, and our previous partnership with Trio Clinical Research, we can now offer clients around the world access to innovative, comprehensive and proven development capabilities,” Mr. Donnelly said. “With the constant pressures and challenges currently facing the drug industry, we need to approach drug and device development from a different and more dynamic paradigm.”